Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Digital Technology Consortium Report Provides Window into Future Trends for Digital Marketing Budget, Staffing and Performance Measurement


CHAPEL HILL, N.C., June 22, 2018 /PRNewswire/ -- Pharmaceutical companies are increasingly using digital engagement channels to more effectively communicate with their customers.

Unlike many other operational areas of pharma, the performance of digital marketing can be measured to evaluate the impact and effectiveness of each digital channel. According to a new study by Best Practices, LLC, various reach and conversion metrics were frequently rated to be the most effective measures to assess performance in many digital channels. While overall volume metrics are best suited to measuring SEO performance, many companies prefer actual conversion metrics for bottom-of-the-funnel channels such as branded and non-branded websites and mobile apps. Middle-of-the-funnel activities such as email marketing campaigns are often measured by simple reach metrics, the study found.

"Forge Top-Tier Biopharma Digital Strategy & Experience" is a new report that examines how leading pharma and medical device firms use evolving tools and tactics to educate key customers, enhance reach, raise sales force effectiveness, measure and increase customer satisfaction, and offset declining HCP access. For this research, Best Practices, LLC engaged 21 digital marketing leaders at 19 companies through a benchmarking survey instrument. Nearly 70% of participants serve at the level of director or above.

Download a complimentary report summary at: http://www.best-in-class.com/rr1500.htm. This 72-page study will serve as a resource for driving digital marketing performance in the healthcare industry.

This study is the result of research produced by Best Practices' Digital Technology Consortium, a service that brings together executives from various leading companies around the world to tackle one question:

How do we manage and implement digital technology as an asset not a utility?

Consortium participants will receive results of customized digital technology benchmark studies conducted among members throughout the service year; members will also participate in roundtable peer knowledge exchanges to share best practices in digital technology. Additionally, members will have access to analysis, intelligence and the Best Practices Database for Technology Leaders.

Please contact us with any questions regarding this study or click this link to find out more about the Digital Technology Consortium.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

SOURCE Best Practices, LLC


These press releases may also interest you

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...

at 15:55
Valley Mountain Regional Center ("VMRC") experienced a data security incident that involved personal and / or protected health information belonging to certain current and former patients and has provided notice of this incident to impacted...



News published on and distributed by: